Dihexa Review 2026: The Truth About C-Met, Unknown Dosing, and Cognitive Enhancement

Here's the tension with Dihexa: the animal research is genuinely good; it comes from a credible university lab; the synaptogenesis (new synapse formation) data is published in peer-reviewed Western journals, and the potency number that gets thrown around; "10 million times more potent than BDNF"; is real.

But as of 2026, essentially zero published human clinical trial data exists.

That combination of extreme potency in cell culture, credible institutional origin, and complete absence of human trials creates a risk profile unlike anything else on this site. The compound appears very active at tiny doses. Nobody knows what the right human dose is. Nobody knows the full side effect profile. Nobody knows what happens long-term when you promote synapse formation in a brain that's already working fine.

This review presents the science honestly. It also presents the caution proportionate to what we actually don't know.

Key Takeaways

• Dihexa is a modified derivative of angiotensin IV developed at Washington State University by Joseph Harding and colleagues
• Reported to be approximately seven orders of magnitude (10 million times) more potent than BDNF at inducing synaptogenesis. This is an in vitro (cell culture) finding, not a human cognition result
• Works through the HGF/c-Met receptor system, not traditional angiotensin receptors. c-Met is a known oncogene (cancer-promoting gene); this creates a theoretical cancer concern
• Reversed cognitive deficits in scopolamine-treated rats (a model mimicking Alzheimer's-like impairment) when given orally
• Unusually for a peptide, Dihexa is orally bioavailable and crosses the blood-brain barrier
• No published human trial data exists as of April 2026
• Psychoactive effects reported by community users: vivid dreams, heightened emotional processing, anxiety
• Research was designed for neurodegeneration, not cognitive enhancement in healthy brains
• Not FDA-approved. Research chemical with significant knowledge gaps

Dihexa, In Simple Terms

• What synapses are: The connections between your brain cells. Every thought, memory, and skill you have exists as a pattern of synaptic connections. Forming new ones (synaptogenesis) is how your brain learns, adapts, and repairs.
• What angiotensin IV is: Most people associate angiotensin with blood pressure. But angiotensin IV is a short peptide fragment that, surprisingly, affects memory and learning in the brain. Dihexa is a stabilized, modified version of this fragment, engineered to survive digestion and cross the blood-brain barrier.
• What Dihexa appears to do: In animal models, it promotes the physical construction of new synaptic connections, primarily in the hippocampus (the brain's memory center). It does this by activating HGF (hepatocyte growth factor) and its receptor c-Met. Animals with chemically induced memory deficits recovered to near-normal cognitive performance after Dihexa treatment.
• The honest gap: All of this is animal data. No human trials. The potency number comes from cells in a dish. Nobody knows whether promoting extra synaptogenesis in a healthy human brain is beneficial, neutral, or potentially disruptive. That question hasn't been asked in a controlled setting, let alone answered.
• The caution: This compound deserves more caution than most on this list. Not because the research is bad, but because the research is incomplete and the compound is extremely potent.

Table of Contents

1. What is Dihexa?
2. The renin-angiotensin system and cognition
3. How it works
4. The 10 million times BDNF figure
5. Oral bioavailability
6. Dosing
7. What does the evidence show?
8. The human evidence gap
9. Community use vs research intent
10. The c-Met cancer concern
11. Psychoactive and mood effects
12. Seizure threshold and neural excitability
13. Bioaccumulation and hepatic safety
14. Stacking and interactions
15. Safety and side effects
16. What happens when you stop?
17. Legal status
18. Unanswered questions
19. Final take
20. FAQ

What is Dihexa?

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, developmental code PNB-0408) is a synthetic oligopeptide (short peptide) derived from angiotensin IV. It was developed at Washington State University by Joseph Harding, Jay Wright, and colleagues over more than 20 years of research into the brain's renin-angiotensin system.

The backstory: angiotensin IV showed promising cognitive effects in animals but degraded in minutes and couldn't cross the blood-brain barrier. Harding's lab identified the three N-terminal amino acids as the minimum unit for cognitive activity, then modified the molecule's ends to block enzymatic degradation and increase lipophilicity (fat solubility, which helps it cross the BBB). The result was Dihexa: metabolically stable, orally active, and brain-penetrant.

The Renin-Angiotensin System and Cognition

Most people know angiotensin from blood pressure. But the brain has its own renin-angiotensin system (RAS) that's separate from the cardiovascular one. Angiotensin IV, a fragment of angiotensin II, binds to what was originally called the AT4 receptor in the hippocampus.

Here's where the science has evolved: the AT4 receptor's identity is currently debated. One group (Albiston and colleagues) presented evidence that it's IRAP (insulin-regulated aminopeptidase). Harding's group presented evidence that the cognitive effects actually operate through the HGF/c-Met receptor system rather than AT4 directly. This distinction matters because HGF/c-Met is a completely different signaling pathway with its own implications, including cancer biology.

How Dihexa Works

Dihexa binds to hepatocyte growth factor (HGF) with high affinity and potentiates (amplifies) HGF's activity at the c-Met receptor. It facilitates HGF dimerization (pairing of HGF molecules), which triggers c-Met phosphorylation and activates downstream signaling cascades including PI3K/Akt and MAPK/ERK pathways.

The downstream result: synaptogenesis and spinogenesis (formation of new dendritic spines, the tiny protrusions on neurons where synapses form) in hippocampal neurons. In the 2014 Benoist et al. study, even subthreshold concentrations of Dihexa combined with subthreshold HGF produced maximal synaptogenic responses; suggesting they work through a common receptor pathway.

Dihexa crosses the blood-brain barrier because of its small size and engineered lipophilicity. Unlike large proteins like BDNF that can't penetrate the BBB, Dihexa's modified chemical structure allows it to pass from the bloodstream into brain tissue after oral administration.

The 10 Million Times BDNF Figure: What It Means and What It Doesn't

This number is real. It's published. And it's almost always presented without context.

The finding: in cell culture synaptogenesis assays, Dihexa was active at picomolar concentrations (trillionths of a mole per liter). BDNF requires nanomolar concentrations (billionths) for equivalent synaptogenic effects. The molar potency difference is approximately seven orders of magnitude. That's where "10 million times" comes from.

What this tells you: Far less Dihexa is needed compared to BDNF to produce the same synapse-forming effect in a dish.

What this does NOT tell you: Whether this translates to human cognition. What the equivalent human dose would be. Whether more synaptogenesis is always beneficial in a living brain. Whether the effect profile in a complex nervous system matches the cell culture result.

BDNF acts through TrkB receptors. Dihexa acts through HGF/c-Met. These are completely different pathways with different downstream effects. Comparing their molar potency on one assay endpoint is real science. Extrapolating that to "Dihexa is 10 million times better for your brain than BDNF" is not.

Oral Bioavailability: Why This Matters

In the McCoy et al. study, oral Dihexa (2 mg/kg) reversed scopolamine-induced cognitive deficits in rats, confirming it survives digestion, reaches the bloodstream, and crosses into the brain in active form.

This is unusual for a peptide. It's possible because Dihexa is small, lipophilic, and metabolically stabilized by the chemical modifications Harding's team engineered. Transdermal (through-the-skin) application is also used in the community.

Dihexa Dosing

Here's the honest answer: nobody knows the right human dose.

What animal studies used: 2 mg/kg oral in rats for cognitive deficit reversal. Intracerebroventricular (directly into the brain) dosing was in the picomolar range.

What the community uses: Typically 10 to 40 mg oral or sublingual daily. Some protocols use transdermal delivery. These doses are extrapolated from animal data with no human pharmacokinetic validation.

Why this matters more here than elsewhere: The extreme potency means dosing errors have more potential consequence. And because the human half-life is entirely unknown, daily dosing carries a real bioaccumulation risk. If a compound this potent builds up systemically day after day, the toxicity ceiling is a complete unknown.

This is not a compound to dose casually. Talk to a clinician.

What Does the Dihexa Evidence Show?

Alzheimer's Disease Animal Models

The McCoy et al. (2013) study in the Journal of Pharmacology and Experimental Therapeutics showed Dihexa reversed cognitive deficits in scopolamine-treated rats (a standard model for Alzheimer's-like impairment).

Parkinson's Disease

Harding's group published a review covering Dihexa's potential in both Alzheimer's and Parkinson's disease (Progress in Neurobiology, 2015), noting the compound's effects on motor function systems alongside cognition. This is an underreported research direction.

Synaptogenesis Data

In hippocampal cell cultures, Dihexa and its parent compound induced spinogenesis and synaptogenesis that was dependent on HGF/c-Met activation. When the c-Met pathway was blocked with an inhibitor, the cognitive effects disappeared. That's clean mechanistic confirmation.

The Human Evidence Gap

As of 2026, essentially no published human trial data exists for Dihexa. This is not a minor footnote. It is the single most important fact about this compound for anyone considering using it.

A related compound, fosgonimeton (ATH-1017), was developed by Athira Pharma (a WSU spin-off) and entered human clinical trials for Alzheimer's. However, data integrity questions involving a co-author surfaced in 2021, and an expression of concern was issued on one of the key papers. The clinical program's status remains complicated.

Dihexa Between Community Use & Research Intent

The research was designed for neurodegeneration; brains that are losing synaptic connections and need them rebuilt. The community uses Dihexa primarily for cognitive enhancement in healthy individuals.

Whether inducing additional synaptogenesis in an already-functioning brain is beneficial, neutral, or potentially disruptive is genuinely unknown. More synapses isn't automatically better. The brain prunes unnecessary connections for a reason. Disrupting that balance in a healthy neural network has never been studied.

This isn't alarmism. It's a real scientific question that nobody has answered.

A specific warning about pediatric and ASD use: Dihexa has appeared in biohacker communities as an experimental treatment for autism spectrum disorder and developmental delays in children. Given the synaptogenesis mechanism, deploying this compound in developing brains without clinical oversight is extremely concerning. Developing brains are actively wiring; flooding that process with an untested synaptogenic agent is not a reasonable risk.

The c-Met Cancer Concern for Dihexa

This deserves its own section, the same way NAD+'s cancer question got its own treatment.

c-Met is a recognized oncogene. Overactivation of c-Met is associated with tumor progression in several cancer types. Dihexa activates c-Met. The question is obvious: does promoting c-Met signaling increase cancer risk?

The WSU patent notes that "short duration safety studies with Dihexa have uncovered no apparent toxicity" and "no neoplastic (cancer) induction," adding that oncogenesis typically requires multiple mutations. That's reassuring but limited; "short duration" animal studies cannot rule out long-term cancer promotion in humans.

The honest framing: the theoretical concern is real and mechanistically grounded. The animal safety data doesn't show cancer. But nobody has studied long-term c-Met activation in humans from Dihexa use. If you have any cancer history, this compound warrants extreme caution.

Psychoactive and Mood Effects of Dihexa

Community users consistently report vivid dreams, intensified emotional processing, and in some cases anxiety. These aren't trivial. They indicate real central nervous system activity.

The angiotensin system has established roles in stress response and anxiety. Dihexa's interaction with brain RAS pathways provides a plausible mechanistic basis for mood and anxiety effects. These reports are the best real-world signal available for what Dihexa does in human brains; and they suggest the compound is psychoactive in ways that go beyond simple "cognitive enhancement."

Dihexa’s Seizure Threshold and Neural Excitability

Rapid, unregulated synaptogenesis can alter the balance between excitatory (glutamate) and inhibitory (GABA) signaling in the brain. In theory, increasing synaptic density could lower the seizure threshold (the point at which the brain tips from normal activity into seizure). No seizure data exists for Dihexa in any published study. But the concern is mechanistically logical; anyone with epilepsy or a seizure history should not use this compound.

Bioaccumulation and Hepatic Safety of Dihexa

Dihexa's oral bioavailability means it undergoes first-pass metabolism in the liver. No human data exists on liver enzyme elevation, hepatotoxicity (liver damage), or long-term hepatic safety. Given that the human half-life is completely unknown, daily dosing protocols could produce systemic accumulation. For a compound this potent, that's a meaningful safety blind spot.

Dihexa: Stacking and Interactions

Dihexa is frequently combined with other nootropics (Semax, Selank, cerebrolysin, racetams). The interaction data with anything on this list or elsewhere essentially doesn't exist. Given the potency and the HGF/c-Met pathway involvement, this isn't a routine disclaimer. It's a meaningful gap.

Safety and Side Effects of Dihexa

The honest answer: the human safety profile is largely unknown.

Animal data: Short-duration studies showed no apparent toxicity. No neoplastic induction in animal models.

Community reports: Vivid dreams, emotional intensity, occasional anxiety, headaches. Some users report cognitive benefits (clarity, memory). The sample is self-selected and uncontrolled.

Theoretical concerns: c-Met oncogene activation, seizure threshold lowering, bioaccumulation from unknown half-life, hepatic toxicity from first-pass metabolism, uncontrolled synaptogenesis in healthy brains.

What Happens When You Stop Dihexa?

No dependency or withdrawal reported in community use. Cognitive effects appear to fade. But here's the specific question nobody can answer: if Dihexa promotes structural synapse formation, what happens to those synapses when dosing stops? Do they persist? Degrade? Integrate normally? The reversibility of drug-induced synaptogenesis is genuinely unknown. This is a more specific and important question than simple dependency.

Legal Status of Dihexa

Research chemical everywhere. No drug approval. No clear pathway to approval currently visible. The Athira Pharma clinical program (fosgonimeton) remains complicated by data integrity concerns.

Unanswered Questions

1. Will properly designed human trials happen? The Athira/fosgonimeton path is uncertain. Academic interest exists but funding is unclear.
2. What is the actual safe and effective human dose range? Unknown. Community protocols are extrapolations from rat data.
3. Does synaptogenesis enhancement benefit healthy brains? Never tested. The brain prunes synapses for a reason.
4. What are the long-term effects of c-Met activation? Short-term animal data shows no cancer. Long-term human data doesn't exist.
5. What is the human half-life? Unknown. This makes bioaccumulation risk impossible to quantify.

Final Take

The animal research is genuinely striking. It comes from a credible university lab. The synaptogenesis data is published in respected pharmacology journals. The oral bioavailability and BBB penetration solve real problems that have limited other neurotrophic compounds.

But the human evidence gap here is larger than almost anywhere else on this site. The potency that makes Dihexa intellectually fascinating is also what makes the absence of human trials a real concern. An extremely active compound with unknown human pharmacokinetics, unknown long-term safety, and a mechanism that involves an oncogene is not something to approach casually.

Intellectually fascinating, practically undertested. If you're going to use it, understand exactly what you don't know.

FAQ

What is Dihexa?

A synthetic derivative of angiotensin IV developed at WSU. It promotes synaptogenesis through the HGF/c-Met pathway.

Is it really 10 million times more potent than BDNF?

In a specific cell culture synaptogenesis assay, yes. That doesn't mean it's 10 million times better for your brain. Different pathways, different receptors, different context.

Has it been tested in humans?

No published human clinical trial data exists as of 2026.

Can you take it orally?

Yes. Dihexa is orally bioavailable and crosses the blood-brain barrier. Unusual for a peptide.

Does it cause cancer?

Unknown. c-Met is an oncogene. Short-term animal studies showed no cancer. Long-term human data doesn't exist.

What about the vivid dreams and anxiety?

Consistently reported by users. Likely related to Dihexa's interaction with the brain's angiotensin system, which has roles in stress and emotional processing.

Should I use it for general cognitive enhancement?

The research was designed for neurodegeneration. Whether promoting synaptogenesis in a healthy brain is beneficial is unknown.

Is it safe for children or people with ASD?

No safety data exists for pediatric use. Using an untested synaptogenic compound in developing brains without clinical oversight is extremely risky.

Is it FDA-approved?

No. Research chemical only.